Abstract
Regulators globally are facing increasing challenges to make decisions regarding subtle effects and risks of pharmacodynamic compounds found in the environment. There is a recognized need for rapid screening tools as well as development of methods to support the further prioritization and testing of these compounds. It is becoming evident that the current standardized experimental designs and predictive models are not specific enough to predict the chronic and long term toxicity of active pharmaceutical ingredients. Novel approaches to firstly screen and prioritize the compounds e.g. by (quantitative) structure-activity relationship modeling and inter-species extrapolation tools are currently proving difficult to develop for chronic effects. Novel toxicogenomic high through-put screening tools may be useful for more rapidly developing toxicogenomic hypothesis and molecular initiating events especially for pharmacodynamic compounds with relatively well described mechanisms of action. The molecular initiating events can then be entered into the proposed adverse outcome pathway which can then indicate the relevant test design to demonstrate the anticipated adverse chronic effects.
Keywords: AOP, API, acute, chronic, aquatic, environmental toxicity, Chronic Toxicity, High-throughputscreening, Toxicogenomics, pharmacodynamic compounds
Current Drug Safety
Title:Challenges and Directions for Regulatory Use of QSARs for Predicting Active Pharmaceutical Ingredients Environmental Toxicity
Volume: 7 Issue: 4
Author(s): Hans Sanderson
Affiliation:
Keywords: AOP, API, acute, chronic, aquatic, environmental toxicity, Chronic Toxicity, High-throughputscreening, Toxicogenomics, pharmacodynamic compounds
Abstract: Regulators globally are facing increasing challenges to make decisions regarding subtle effects and risks of pharmacodynamic compounds found in the environment. There is a recognized need for rapid screening tools as well as development of methods to support the further prioritization and testing of these compounds. It is becoming evident that the current standardized experimental designs and predictive models are not specific enough to predict the chronic and long term toxicity of active pharmaceutical ingredients. Novel approaches to firstly screen and prioritize the compounds e.g. by (quantitative) structure-activity relationship modeling and inter-species extrapolation tools are currently proving difficult to develop for chronic effects. Novel toxicogenomic high through-put screening tools may be useful for more rapidly developing toxicogenomic hypothesis and molecular initiating events especially for pharmacodynamic compounds with relatively well described mechanisms of action. The molecular initiating events can then be entered into the proposed adverse outcome pathway which can then indicate the relevant test design to demonstrate the anticipated adverse chronic effects.
Export Options
About this article
Cite this article as:
Sanderson Hans, Challenges and Directions for Regulatory Use of QSARs for Predicting Active Pharmaceutical Ingredients Environmental Toxicity, Current Drug Safety 2012; 7 (4) . https://dx.doi.org/10.2174/157488612804096597
DOI https://dx.doi.org/10.2174/157488612804096597 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Structure-Activity Relationships of Natural and Synthetic Indole-Derived Scaffolds as α-Glucosidase Inhibitors: A Mini-Review
Mini-Reviews in Medicinal Chemistry Editorial
Current Nutraceuticals Design, Synthesis and Biological Evaluation of Carbazole Derivatives as Antitubercular and Antibacterial Agents
Current Bioactive Compounds Synthesis and Inhibitory Effects of Some Novel 1,3-diarylprop-2-en-1-one Analogues in Foxp3 Expression: A Novel Class of Anti-cancer Candidates
Medicinal Chemistry Concise Review of the Rationale for Pulmonary Embolism Treatment and Endovascular Device Therapies
Current Cardiology Reviews A Revision of Polymeric Nanoparticles as a Strategy to Improve the Biological Activity of Melatonin
Current Medicinal Chemistry Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery Recent Advances in Thrombopoietic Small Molecules
Current Bioactive Compounds Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Current Topics in Medicinal Chemistry A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Therapeutic Targets in Respiratory Viral Infections
Current Medicinal Chemistry Pharmacological Management of PDA: Oral Versus Intravenous Medications
Current Clinical Pharmacology Construction, Expression, Purification and Biotin Labeling of a Single Recombinant Multi-Epitope Antigen for Double-Antigen Sandwich ELISA to Detect Hepatitis C Virus Antibody
Protein & Peptide Letters Recent Advances in QSAR and Their Applications in Predicting the Activities of Chemical Molecules, Peptides and Proteins for Drug Design
Current Protein & Peptide Science Virtual Screening for Novel Staphylococcus Aureus NorA Efflux Pump Inhibitors From Natural Products
Medicinal Chemistry Chemotherapy-induced Pulmonary Toxicity Mimicking COVID-19 Pneumonia
Current Medical Imaging Common SAR Derived from Linear and Non-linear QSAR Studies on AChE Inhibitors used in the Treatment of Alzheimer's Disease
Current Neuropharmacology Microwave Assisted Organic Synthesis (MAOS) of New Dispacamide A Derivatives Bearing a Thiazolinone Platform, Biological Assays on Inhibition of Protein Kinases and Cell Effects
Current Microwave Chemistry